{"id":"NCT01185782","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women","officialTitle":"Parallel-Group Comparative Study of SJ-0021 and Purified Pituitary Gonadotropin in Subjects With Amenorrhea I or Anovulatory Cycles - Phase III Single-Blind Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2007-12","completion":"2007-12","firstPosted":"2010-08-20","resultsPosted":"2012-02-24","lastUpdate":"2013-12-27"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Infertility","Ovulation Induction"],"interventions":[{"type":"DRUG","name":"Gonalef® (Follitropin alfa)","otherNames":["Gonalef®","follitropin alfa","recombinant human follicle-stimulating hormone","r-hFSH","SJ-0021"]},{"type":"DRUG","name":"Purified pituitary gonadotropin (Fertinorm-P®)","otherNames":["Fertinorm-P®","purified urinary human follicle-stimulatin hormone","urofollitropin","u-hFSH"]}],"arms":[{"label":"SJ-0021 group","type":"EXPERIMENTAL"},{"label":"Purified pituitary gonadotropin group","type":"ACTIVE_COMPARATOR"}],"summary":"Efficacy and safety studies in the past have suggested that a starting dose of 75 International Unit (IU) of SJ-0021, and an increase in the dose by 37.5 IU every 7 days, are safe for treatment of subjects with ovulatory disorders who are infertile due to hypothalamic or pituitary dysfunction and have amenorrhea I or anovulatory cycles (including oligomenorrhea and polymenorrhea).\n\nThis was a phase III, multicentre, single-blind, parallel-group comparative study conducted to provide confirmatory evidence of non-inferiority of SJ-0021 versus purified gonadotropin, a comparator drug, for induction of follicle development and ovulation in infertile Japanese women and to provide further information on the safety and tolerability of SJ-0021.","primaryOutcome":{"measure":"Percentage of Participants With Ovulation","timeFrame":"On Day 6±1 or 9±1 days during post-treatment assessment period (Day 35-42 of post-treatment period for clinical pregnancy)]","effectByArm":[{"arm":"SJ-0021","deltaMin":79.1,"sd":null},{"arm":"u-hFSH","deltaMin":82.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["29699333"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":129},"commonTop":["Nasopharyngitis","Abdominal pain lower","Abdominal distension","Headache","Ovarian hyperstimulation syndrome"]}}